Buy Gidazepam Pellets 3mg for Advanced Laboratory Research in the USA and Europe

Gidazepam pellets 3mg (systematically designated as 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1-(2-phenylacetyl)-2H-1,4-benzodiazepin-2-one, gidazepam, or hidazepam; CAS Registry Number: 129186-29-4) represent a critical analytical reference standard within the atypical 1,4-benzodiazepine class of designer benzodiazepines and prodrugs, serving indispensable roles in forensic toxicology, GABA-A receptor and TSPO pharmacology, and mass spectral library development for European and USA laboratory environments. As a bromo-fluoro-benzodiazepine prodrug that undergoes rapid N-deacetylation to the highly potent active metabolite desalkylgidazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one), this compound is essential for novel psychoactive substance (NPS) monitoring, sedative-hypnotic screening, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade Gidazepam pellets at 3mg strength with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.

Uncompromising Purity and Analytical Characterisation

Every batch of Gidazepam Pellets (3mg) supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as Gidazepam freebase), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-HRMS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing Gidazepam from related benzodiazepines such as desalkylgidazepam, phenazepam, bromazepam, flubromazepam, and other bromo- or fluoro-substituted 1,4-benzodiazepin-2-one derivatives.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final pellet compression and packaging. Certificates of Analysis specify desalkylgidazepam impurity <0.10%, phenazepam <0.07%, bromazepam metabolites <0.11%, process unknowns <0.15%, and total impurities <1.0%, with pellet contents exceeding 98% purity orthogonally validated through gradient reversed-phase UHPLC (BEH C18 1.7 μm, 0.3 mL/min, 10–50% ACN/0.1% formic acid gradient) resolving >98.5% main peak versus desbromo (<0.04%) and N-deacetyl (<0.03%) impurities, quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic proton integration ratios, Q-TOF MS (ESI+ accurate mass m/z 387.0489 [M+H]⁺, <2 ppm error), and headspace GC-MS (residual solvents DMF <880 ppm, IPA <5000 ppm ICH Q3C compliant).academic.oup+11

The physical presentation of Gidazepam as white to off-white compressed pellets offers distinct advantages for analytical flexibility: each pellet contains a precisely measured 3mg aliquot of Gidazepam, facilitating rapid dissolution and homogeneous stock solution preparation in organic solvents. This pelletised form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays and mass spectral calibration protocols. The pellets undergo uniformity testing to confirm consistent mass and compound distribution across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. Gidazepam has been reported as a crystalline solid with molecular formula C₂₃H₁₈BrFN₂O₂ and molecular weight 453.31 g/mol.academic.oup+11

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for benzodiazepine prodrug and designer benzodiazepine detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for Gidazepam explicitly depend on having pure reference material from suppliers such as Cayman Chemical (Item No. 36421, purity ≥95%) and LGC Standards for retention time and mass spectral data verification, with metabolism studies confirming rapid N-deacetylation to desalkylgidazepam in biological matrices.academic.oup+11

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: Gidazepam serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, impaired driving investigations, post-mortem analysis, and urine/blood screening. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, and oral fluid, supporting method validation for confirmatory testing protocols targeting 1,4-benzodiazepine prodrugs and designer benzodiazepines. European and USA forensic laboratories utilise Gidazepam reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the benzodiazepine class. Validated MRM transitions for Gidazepam detection include the molecular ion [M+H]⁺ at m/z 387.0489 (exact mass for C₂₃H₁₉BrFN₂O₂⁺) and characteristic bromo-fluoro-benzodiazepine and phenylacetyl fragments, with molecular formula C₂₃H₁₈BrFN₂O₂ and molecular weight 453.31 g/mol enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 1–10 ng/mL in urine and blood matrices. Gidazepam and its active metabolite desalkylgidazepam have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions, with metabolism studies confirming rapid N-deacetylation in biological matrices.academic.oup+11

GABA-A Receptor and TSPO Pharmacology: Within strictly controlled in vitro modelling frameworks, Gidazepam reference material supports receptor-binding affinity studies at GABA-A receptor subtypes and the translocator protein (TSPO, formerly peripheral benzodiazepine receptor), as well as functional positive allosteric modulation and neurosteroid synthesis assays using transfected cell lines expressing specific receptor subunit compositions. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), and structure-activity relationships within the atypical 1,4-benzodiazepine class. Gidazepam acts as a partial agonist of GABA-A receptors with low affinity (Kᵢ = 2200 ± 50 nM), but exhibits three-fold higher affinity for TSPO (IC₅₀: 710 nM) than central nervous system benzodiazepine receptors, suggesting it functions as a prodrug at GABA-A receptors via metabolism to desalkylgidazepam (Kᵢ = 3.5 ± 0.2 nM) while acting as a TSPO agonist to stimulate neurosteroid synthesis. In research models, Gidazepam exhibits prodrug characteristics, with therapeutic doses in the range of 50–200 mg/day for anxiety and 60 mg for migraine treatment, while active metabolite doses in misuse are described as 3–9 mg and traded online as 1–3 mg pellets. The 7-bromo-5-(2-fluorophenyl)-1-(2-phenylacetyl) substitution pattern on the 1,4-benzodiazepin-2-one core confers distinct pharmacological properties compared to 7-bromo (bromazepam), 7-chloro (diazepam), or 2′-chloro (phenazepam) analogues, making it a valuable reference compound for dissecting halogen substituent and N-acyl effects on GABA-A receptor binding affinity, TSPO agonism, metabolic stability, and cytochrome P450 interactions. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols.academic.oup+12

Chemical Synthesis & Reaction Monitoring: As a high-purity bromo-fluoro-benzodiazepine prodrug, Gidazepam functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting GABA-A receptor and TSPO modulators. The 7-bromo-5-(2-fluorophenyl)-1-(2-phenylacetyl)-1,4-benzodiazepin-2-one structure imparts distinct electronic and steric properties compared to 7-bromo (bromazepam), 7-chloro (diazepam), or N-desacyl (desalkylgidazepam) analogues, making this compound valuable for structure-activity relationship (SAR) studies examining halogen substituent and N-acyl effects on receptor binding affinity, metabolic stability, and cytochrome P450 interactions. Analytical chemists employ Gidazepam as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related benzodiazepines, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics.academic.oup+12

Method Validation & Calibration: Gidazepam pellets (3mg per pellet) provide a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays, with each pellet containing a precisely defined 3mg aliquot of Gidazepam. The pelletised form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing benzodiazepine prodrug and designer benzodiazepine samples. Standard preparation protocols recommend dissolving one pellet in 3mL of methanol or acetonitrile to yield an exact 1 mg/mL stock solution, then further diluting to working concentrations of 0.1–10 µg/mL for GC-MS or LC-MS/MS injection. This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for Gidazepam are supplied as compressed pellets with molecular weight 453.31 g/mol (C₂₃H₁₈BrFN₂O₂) and purity ≥98%.academic.oup+11

Compound Stability, Optimal Storage, and Safe Handling Protocols

Gidazepam pellets, as a bromo-fluoro-benzodiazepine prodrug and designer benzodiazepine, exhibit moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation (N-deacetylation to desalkylgidazepam) when exposed to ambient atmospheric conditions, light, and moisture. The compressed pellet form confers baseline protection, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store Gidazepam pellets in their original amber glass or opaque plastic bottles at +4°C (refrigerated conditions), protected from light and moisture. Ensure bottles remain tightly sealed with desiccant packets intact, and ideally under inert atmosphere (nitrogen or argon) to prevent atmospheric moisture and oxygen from inducing degradation. Equilibrate bottles to room temperature in a desiccator before opening to minimise condensation formation on pellet surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer Gidazepam pellets to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—Gidazepam pellets maintain specification compliance for 24–36 months, as evidenced by stability data on analogous benzodiazepine reference standards. Avoid repeated freeze-thaw cycles by aliquoting pellets into single-use vials before freezing.caymanchem+7

Safe Handling Prerequisites: All handling of Gidazepam pellets must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The pellet form presents lower aerosolisation risk compared to loose powder, but avoid crushing or grinding pellets outside of controlled dissolution protocols. For stock solution preparation, Gidazepam demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.1–10mM or higher. Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of Gidazepam and related benzodiazepines in many jurisdictions (scheduled as a Class C drug in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation, and subject to analogue act enforcement in the USA as a designer benzodiazepine), implement additional security protocols to prevent unauthorised access or diversion. Gidazepam is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in impaired driving, overdose, and post-mortem investigations.academic.oup+11

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and GABA-A receptor/TSPO pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final pellet compression and packaging—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of Gidazepam in the UK (Class C), multiple EU member states, and potential analogue act enforcement in the USA, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic benzodiazepine prodrug method validation, mass spectral library development, and GABA-A receptor/TSPO pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.